IRLAB obtains strengthened patent protection for Phase II candidate pirepemat

IRLAB (Nasdaq Stockholm: IRLAB A) today announced that the company has been granted a new patent on the manufacturing process for the drug candidate pirepemat by the US Patent Office. Pirepemat is one of IRLAB’s clinical drug candidates and under development in Phase IIb for the treatment of impaired balance and falls in Parkinson’s disease. IRLAB (Nasdaq Stockholm: IRLAB A) today announced that the company has been granted a new patent on the manufacturing process for the drug candidate pirepemat by the US Patent Office. Pirepemat is one of IRLAB’s clinical drug candidates and under development in Phase IIb for the treatment of impaired balance and falls in Parkinson’s disease. The granted patent, US 11,078,158 B2, specifically covers a chemical process for manufacturing pirepemat in its pure form. This is critical to secure the future production of pirepemat in industrial scale once a drug based on pirepemat is approved and available on the market. “We are pleased to successfully make progress in strengthening our clinical project portfolio’s patent protection. The US is one of the largest and key markets, which makes this issued patent a valuable addition to the commercial potential of pirepemat,” said Nicholas Waters, CEO at IRLAB. For more information Nicholas Waters, CEO Phone: +46 730 75 77 01 E-mail: [email protected] Viktor Siewertz, CFO Phone: +46 727 10 70 70 E-mail: [email protected] About pirepemat (IRL752) Pirepemat is in development for the treatment of impaired balance (postural dysfunction) and falls in Parkinson’s disease. The results from a clinical Phase IIa study indicate that pirepemat has the potential to improve balance and reduce the risk of falls. Pirepemat has the ability to increase the levels of the neurotransmitters norepinephrine and dopamine in the frontal cortex and activate specific genes involved in nerve cell connections. In clinical research, it has been shown that the neurotransmitters noradrenaline and dopamine are decreased in the frontal cortex in Parkinson’s disease. This could be counteracted by treatment with pirepemat, leading to improvement of balance, cognitive and psychiatric symptoms for these patients. A Phase IIb study to evaluate the effect of pirepemat on fallrate is planned to begin in 2021. About IRLAB IRLAB is a Swedish research and development company that focuses on developing novel treatments in Parkinson’s disease. The company's most advanced candidates, mesdopetam (IRL790) and pirepemat (IRL752), have completed Phase IIa studies and are designed to treat some of the most difficult symptoms related to Parkinson's disease: involuntary movements (PD-LIDs), psychosis (PDP) and symptoms linked to cognitive decline such as impaired balance and increased risk of falls (PD-Falls). Through the proprietary research platform, ISP (the Integrative Screening Process), IRLAB discovers and develops unique drug candidates for central nervous system (CNS)-related disorders where large and growing medical needs exist. In addition to the clinical candidates, the ISP platform has also generated several CNS programs that are now in preclinical phase. The project portfolio comprises a combination of the fully-funded mesdopetam program, run in collaboration with global partner Ipsen, as well as innovative in-house programs from preclinical to Phase IIb. IRLAB is listed on Nasdaq Stockholm Main Market. More information on www.irlab.se .

The release as fetched from its publisher. irlab.se ↗